(Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that results of a Phase 2 clinical trial of mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese patients with overweight or obesity were published in Nature Communications
Insulin secretion was measured after chronic (4 days) culture of WT mouse islets in 5.5 mM (blue) or 25 mM (red) glucose ( n = 8 for each condition)
At Greenwald Law Firm, we offer a free initial consultation to all new clients
Common questions about empagliflozin, NHS (2023) Empagliflozin tablets, Cleveland Clinic (2025) Euglycemic diabetic ketoacidosis, StatPearls (2023) Taking empagliflozin with other medicines and herbal supplements, NHS (2023) Empagliflozin (oral route), Mayo Clinic (2025) Highlights of prescribing information, Food and Drug Administration (2023) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
The Risk Profile: The nuance here is in the fragment part
)
